Prospects for cannabinoid therapies in basal ganglia disorders.
Subject: Parkinson's Disease - PUBLISHED VIA British Journal of Pharmacology
Author(s):
Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.
View Source >>
Related Studies:
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.
Published via Journal of Clinical Pharmacy and Therapeutics
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties.
Published via Brain Research
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.
Published via Neurobiology of Disease
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.
Published via Journal of Psychopharmacology
Cannabidiol for the treatment of psychosis in Parkinson’s disease.
Published via Journal of Psychopharmacology